CD4+ T cells are essential for protection against viruses, including SARS-CoV-2. The
sensitivity of CD4+ T cells to mutations in SARS-CoV-2 variants of concern (VOCs) is poorly …

Antibodies are a potential therapy for severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), but the risk of the virus evolving to escape them remains unclear. Here we …

Unrelated individuals can produce genetically similar clones of antibodies, known as public
clonotypes, which have been seen in responses to different infectious diseases, as well as …

Due to differences in human and murine angiotensin converting enzyme 2 (ACE-2) receptor,
initially available SARS-CoV-2 isolates could not infect mice. Here we show that serial …

After monoclonal antibody sotrovimab implementation, Rockett et al have warned on March
9th about two resistant mutations in the spike at position 337 and 340 occurring within the …

Ever since the breakout of COVID-19 disease, ceaseless genomic research to inspect the
epidemiology and evolution of the pathogen has been undertaken globally. Large scale viral …

Tracking evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
within infected individuals will help elucidate coronavirus disease 2019 (COVID-19) …

Background Antispike monoclonal antibodies are recommended for early treatment of high-
risk persons with mild to moderate coronavirus disease 2019 (COVID-19). However, clinical …

As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve,
several variants of concern (VOCs) have arisen which are defined by multiple mutations in …

Monoclonal antibodies (mAbs) have been known since the 1970s. However, their
therapeutic potential in the medical field has recently emerged, with the advancement of …